BR112021017584A2 - Regime e composições de imunização contra hepatite b - Google Patents

Regime e composições de imunização contra hepatite b

Info

Publication number
BR112021017584A2
BR112021017584A2 BR112021017584A BR112021017584A BR112021017584A2 BR 112021017584 A2 BR112021017584 A2 BR 112021017584A2 BR 112021017584 A BR112021017584 A BR 112021017584A BR 112021017584 A BR112021017584 A BR 112021017584A BR 112021017584 A2 BR112021017584 A2 BR 112021017584A2
Authority
BR
Brazil
Prior art keywords
hepatitis
human
administering
composition
hbc
Prior art date
Application number
BR112021017584A
Other languages
English (en)
Inventor
Babak Bayat
Marie Madeleine Lorin Clarisse
Eve-Renee Warter Lucile
Kiyoshi Hamatake Robert
Kieffer You Shihyun
Bojidarov Vassilev Ventzislav
Original Assignee
Glaxosmithkline Biologicals Sa
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112021017584A2 publication Critical patent/BR112021017584A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

regime e composições de imunização contra hepatite b. é fornecido um método para tratar infecção por hepatite b crônica (chb) e/ou infecção por hepatite d crônica (chd) em um humano, compreendendo as etapas de: a) administrar ao humano uma composição compreendendo um oligonucleotídeo anti-sentido (aso) de 10 a 30 nucleosídeos em comprimento, alvejado para um ácido nucleico de hbv (um aso de hbv); b) administrar ao humano uma composição compreendendo um vetor adenoviral de chimpanzé (chad) defeituoso de replicação compreendendo um polinucleotídeo que codifica um antígeno de superfície de hepatite b (hbs) e um ácido nucleico que codifica um antígeno de núcleo do vírus da hepatite b (hbc); c) administrar ao humano uma composição compreendendo um vetor do vírus vaccinia ankara modificado (mva) compreendendo um polinucleotídeo que codifica um antígeno de superfície de hepatite b (hbs) e um ácido nucleico que codifica um antígeno de núcleo do vírus da hepatite b (hbc); e d) administrar ao humano uma composição compreendendo um antígeno de superfície de hepatite b (hbs) recombinante, antígeno de núcleo do vírus da hepatite b (hbc) recombinante e um adjuvante.
BR112021017584A 2019-03-05 2020-03-04 Regime e composições de imunização contra hepatite b BR112021017584A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814261P 2019-03-05 2019-03-05
PCT/EP2020/055755 WO2020178359A1 (en) 2019-03-05 2020-03-04 Hepatitis b immunisation regimen and compositions

Publications (1)

Publication Number Publication Date
BR112021017584A2 true BR112021017584A2 (pt) 2021-11-09

Family

ID=69770898

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017584A BR112021017584A2 (pt) 2019-03-05 2020-03-04 Regime e composições de imunização contra hepatite b

Country Status (8)

Country Link
US (1) US20220339281A1 (pt)
EP (1) EP3934687A1 (pt)
JP (1) JP2022524007A (pt)
CN (1) CN113573730A (pt)
BR (1) BR112021017584A2 (pt)
CA (1) CA3132601A1 (pt)
TW (1) TW202102256A (pt)
WO (1) WO2020178359A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114107393A (zh) * 2021-04-07 2022-03-01 上海劲威生物科技有限公司 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用
WO2023131098A2 (en) * 2022-01-10 2023-07-13 Ausper Biopharma Co., Ltd. Modulation of hepatitis b virus (hbv) expression

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
EP1175912A1 (en) 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
SI0729473T1 (en) 1993-11-17 2001-02-28 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
EP1009429B1 (en) 1997-08-29 2009-07-08 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
NZ530245A (en) 2001-06-22 2007-04-27 Wistar Inst Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
PL1711518T3 (pl) 2004-01-23 2010-06-30 St Di Richerche Di Biologia Molecolare P Angeletti S P A Nośniki szczepionek pochodzące od szympansich adenowirusów
SI1957528T1 (sl) 2005-11-30 2013-02-28 University Of Copenhagen Nukleotidno cepivo
HUE045093T2 (hu) 2008-11-21 2019-12-30 Kobenhavns Univ University Of Copenhagen Immunválasz kiváltása
BRPI1008018A2 (pt) 2009-02-02 2016-03-15 Okairos Ag ácidos nucleicos de adenovírus símio e sequências de aminoácidos, vetores contendo os mesmos e uso dos mesmos
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
PT3505528T (pt) 2011-04-21 2021-02-23 Glaxo Group Ltd Modulação da expressão do vírus da hepatite b (vhb)
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2016020538A1 (en) * 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
JP6983665B2 (ja) 2015-06-12 2021-12-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム アデノウイルスポリヌクレオチド及びポリペプチド
EP3402888B1 (en) * 2016-01-12 2020-08-26 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating hbv
GB201705765D0 (en) * 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd HBV vaccine
MA50278A (fr) * 2017-04-18 2020-02-26 Alnylam Pharmaceuticals Inc Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb)
GB201721069D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
GB201721068D0 (en) * 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions

Also Published As

Publication number Publication date
JP2022524007A (ja) 2022-04-27
US20220339281A1 (en) 2022-10-27
WO2020178359A1 (en) 2020-09-10
CN113573730A (zh) 2021-10-29
CA3132601A1 (en) 2020-09-10
TW202102256A (zh) 2021-01-16
EP3934687A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
MX2020006090A (es) Régimen y composiciones de inmunización contra la hepatitis b.
HRP20201873T1 (hr) Sredstva i postupci za liječenje hbv-a
Draper et al. Viruses as vaccine vectors for infectious diseases and cancer
BR112021017584A2 (pt) Regime e composições de imunização contra hepatite b
BR112018012962A2 (pt) vacinas de zika recombinantes
BR112023012303A2 (pt) Vacina de rna contra variantes de sars-cov-2
BR112019021852A2 (pt) Agente de rnai e uma vacina contra hbv, uso ou método e kit para tratamento
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
BR112018009032A8 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
Rahn et al. Vaccines against influenza A viruses in poultry and swine: Status and future developments
BR112022014884A2 (pt) Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
JP2019502371A (ja) マイクロｒｎａ認識エレメントを含むｃｍｖベクター
TW201408309A (zh) 用於治療ｂ型肝炎及ｄ型肝炎感染之方法
BRPI0504945A8 (pt) Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
WO2017156511A8 (en) Live attenuated zika virus vaccine
CL2012000447A1 (es) Composición o vacuna que comprende un vector viral de un paramixovirus aviar 8 (apmv-8) recombinante; método para producir dicho vector; y uso para preparar medicamento útil para inducir una respuesta inmunológica.
BR112017000320A2 (pt) métodos para o tratamento de infecções virais de hepatite b e hepatite d
Mahmood et al. Protection capability of recombinant plasmid DNA vaccine containing VP2 gene of very virulent infectious bursal disease virus in chickens adjuvanted with CpG oligodeoxynucleotide
BR112018076234A2 (pt) vacina contra o vírus da bronquite infecciosa
BR112022023173A2 (pt) Vacinas contra coronavírus com base na vacínia ankara (smva) modificada sintética
BR112022027038A2 (pt) Vacinas de replicon de rna contra hbv
BRPI0813313A8 (pt) Vetor poxvírus de racum recombinante, vacina da raiva recombinante, métodos para induzir uma resposta imunoprotetora para a raiva em um mamífero, e para produzir um vetor poxvírus de racum recombinante, e, plasmídeo pfd2003-gpv-pv.
MX2021010798A (es) Mezclas estabilizadoras de aminas estericamente impedidas.